S Lim’s scientific contributions

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (1)


Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukemia and secondary hypogammaglobulinaemia
  • Article

April 1995

·

19 Reads

·

97 Citations

International Journal of Laboratory Hematology

B.J. BOUGHTON

·

·

S Lim

·

N Smith

Forty-two patients with chronic lymphocytic leukaemia (CLL), serum IgG levels < 5.5 milligrams and a history of two or more recent infections, were randomized to receive infusions of 18 g human intravenous immunoglobulin (IVIg) or human albumin placebo every three weeks. During the 12 month study 122 infections were documented but only four were associated with neutropenia. Ten patients (24%) with IgG levels < 3.0 milligrams experienced 65% of the infections. In response to IVIg there were immediate and accumulative increases in serum IgG levels and an associated decrease in total and serious infections. If three further infections occurred, placebo patients were commenced on 18 g IVIg, and IVIg patients were increased to 24 g IVIg. Approximately 50% of these cases subsequently remained infection free. The study shows the usefulness of prophylactic Sandoglobulin in CLL patients with hypogammaglobulinaemia, and suggests that this may be justified in those with recurrent infections and serum IgG levels < 3 milligrams.

Citations (1)


... IgRT is the mainstay therapy for patients with primary immunodeficiency diseases (PIDs), and therefore the rationale for the use of IgRT in patients with SID is mainly based on clinical experience in the treatment of PIDs [16,17]. Evidence for IgRT use in SID from large randomized controlled clinical trials, particularly those that report on infection and mortality outcomes, is lacking, and the studies that have been conducted were completed in the late 1980s and the 1990s [18][19][20][21]. Since this time, the complexity of SID has increased because the patient populations, therapeutic protocols, and treatment landscape have changed (particularly with the introduction of targeted therapies for CLL [22]), as have the infection outcomes assessed in primary studies. ...

Reference:

Treatment patterns and burden of infection in patients with chronic lymphocytic leukemia and secondary immunodeficiency: a retrospective database study
Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukemia and secondary hypogammaglobulinaemia
  • Citing Article
  • April 1995

International Journal of Laboratory Hematology